alexa Personalized Traditional Chinese Medicine Plus Nucleoside Analogues Of Anti-HBV Infection Therapy And Simulations | 71908
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

12th Euro-Global Gastroenterology Conference

Lequan Min, Xiao Chen, Yu Zheng, Yongmei Su and Yongan Ye
University of Science and Technology Beijing, China
Dongzhimen Hospital - Beijing University of Chinese Medicine, China
ScientificTracks Abstracts: J Gastrointest Dig Syst
DOI: 10.4172/2161-069X-C1-052
Abstract
Statement of the Problem: An estimated 257 million people are living with hepatitis B virus (HBV) infection. In most people, the treatment does not cure hepatitis B infection, but only suppresses the replication of the virus. Therefore, most people who start hepatitis B treatment must continue it for life. Evidences show that traditional Chinese medicine (TCM) may regulate chronic hepatitis B (CHB) patients' immune functions, which is particularly available for personalized antiviral therapy. Mathematical modeling anti- HBV infection therapy can help the medical doctor better to follow the dynamic of viral infection, and understand drug functions. Methodology & Theoretical Orientation: A 57-year-old CHB patient received TCM and nucleoside analogues (NA) combination treatment: TCM, TCM+adefovior dipvoxl (ADV), TCM+ entecavir (ENT), TCM+ADV+ENT, ENT. The TCM consists of main description (about 17 herb ingredients) and sub description (selected from other 17 herb ingredients). The patient’s baseline HBV DNA: 2.7e7 cps/mL, ALT: 45.7 U/L, HBeAg 450.57S/CO. After about 1200 day’s therapy, the patient’s HBV DNA: less 20IU/mL, (the lowest limit of detection), ALT: 43.6 U/L, HBeAg 0.505/CO. Then stopping treatment for about 6 months, and patient’s HBV DNA: 359IU/mL, ALT: 33.8 U/L, HBeAg 0.79/CO. After one month’s ENT monotone therapy, the patient’s HBV DNA: less 20IU/ mL, ALT: 30.7 U/L, HBeAg 0.620/CO. A mathematical model has been proposed to describe the dynamics of the anti-HBV infection treatments. Conclusion & Significance: Both test and simulation evidences show that the TCM plus NA anti-HBV infection therapy may not only suppress chronic HBV patients’ serum HBV-DNA level but also regulate patients’ specific immune functions, which clear HBV directly and almost do not damage patients’ hepatocytes. After stopping the treatments, the activated patient's specific immune function may be kept. TCM + NA combination treatment may be efficient for CHB patients with almost normal ALT.
Biography

Lequan Min was the Professor and PhD supervisor with the School of Mathematics and Physics /School of Automation at the University of Science and Technology, Beijing before he retired. His research interests include modeling and simulations of the dynamics of HBV /HIV infection and anti-HBV/HIV infection treatments; the robust designs of the cellular neural network and image processing; synchronization theories of complex networks with applications. He has co-authored to have proposed the assumption that four classifications for HBV/ HIV infected people. He has been the chief director of four National Natural Science Foundations of China and participated the 11th 5-Year Plan Key Research Project of China: Major infectious diseases AIDS and Viral Hepatitis special. He is the author or coauthor of over 300 scientific journal and conference papers. He has taught over ten undergraduates and graduate courses, and supervised 27 PhD student and 55 Master students.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7